182 related articles for article (PubMed ID: 29520805)
1. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
Kasuki L; Dalmolin MD; Wildemberg LE; Gadelha MR
Clin Endocrinol (Oxf); 2018 Jun; 88(6):889-895. PubMed ID: 29520805
[TBL] [Abstract][Full Text] [Related]
2. The role of combination medical therapy in the treatment of acromegaly.
Lim DS; Fleseriu M
Pituitary; 2017 Feb; 20(1):136-148. PubMed ID: 27522663
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors.
Gatto F; Feelders RA; van Koetsveld PM; Dogan F; Neggers SJCMM; van der Lelij AJ; Amarù J; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2023 Apr; 108(5):e98-e109. PubMed ID: 36413489
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
7. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
8. Brazilian multicenter study on pegvisomant treatment in acromegaly.
Boguszewski CL; Huayllas MKP; Vilar L; Naves LA; Ribeiro-Oliveira Junior A; Soares BS; Czepielewski MA; Abucham J; Correa-Silva SR; Bronstein MD; Jallad RS; Duarte FG; Musolino NR; Kasuki L; Gadelha MR
Arch Endocrinol Metab; 2019 Jul; 63(4):328-336. PubMed ID: 31365632
[TBL] [Abstract][Full Text] [Related]
9. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion.
Biagetti B; Araujo-Castro M; Torre EM; Novoa-Testa I; Cordido F; Corrales EP; Berrocal VR; Guerrero-Pérez F; Vicente A; Percovich JC; Centeno RG; González L; García MDO; Echarri AI; Rodríguez MDM; Novo-Rodríguez C; Calatayud M; Villar-Taibo R; Bernabéu I; Alvarez-Escola C; Valderrama PB; Tenorio-Jiménez C; Galiana PA; Moreno EV; Molero IG; Iglesias P; Blanco C; De Lara FV; de Miguel P; Mezquita EL; Hanzu F; Aldecoa I; Aznar S; Lamas C; Aulinas A; Asla Roca Q; Gracia P; Córdova JMR; Aviles M; Asensio-Wandosel D; Sampedro M; Cámara R; Paja M; Ruz-Caracuel I; Fajardo-Montañana C; Asanza EC; Martinez-Saez E; Marazuela M; Puig-Domingo M
Eur J Endocrinol; 2024 Jun; 190(6):458-466. PubMed ID: 38771697
[TBL] [Abstract][Full Text] [Related]
11. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor ligands in the treatment of acromegaly.
Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D
Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Mattar P; Alves Martins MR; Abucham J
Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.
Nista F; Corica G; Castelletti L; Khorrami K; Campana C; Cocchiara F; Zoppoli G; Prior A; Rossi DC; Zona G; Ferone D; Gatto F
Front Endocrinol (Lausanne); 2021; 12():677919. PubMed ID: 34025586
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Cozzi R; Attanasio R; Barausse M; Dallabonzana D; Orlandi P; Da Re N; Branca V; Oppizzi G; Gelli D
Eur J Endocrinol; 1998 Nov; 139(5):516-21. PubMed ID: 9849816
[TBL] [Abstract][Full Text] [Related]
19. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
20. A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly.
Fleseriu M; Zhang Z; Hanman K; Haria K; Houchard A; Khawaja S; Ribeiro-Oliveira A; Gadelha M
Pituitary; 2023 Feb; 26(1):9-41. PubMed ID: 36447058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
